Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control

被引：85

作者：

Klement, R. J. ^{[1
]}

Guckenberger, M. ^{[2
]}

Alheid, H. ^{[3
]}

Allgaeuer, M. ^{[4
]}

Becker, G. ^{[5
]}

Blanck, O. ^{[6
]}

Boda-Heggemann, J. ^{[7
]}

Brunner, T. ^{[8
]}

Duma, M. ^{[9
]}

Gerum, S. ^{[10
]}

Habermehl, D. ^{[11
]}

Hildebrandt, G. ^{[12
]}

Lewitzki, V. ^{[13
]}

Ostheimer, C. ^{[14
]}

Papachristofilou, A. ^{[15
]}

Petersen, C. ^{[16
]}

Schneider, T. ^{[17
]}

Semrau, R. ^{[18
]}

Wachter, S. ^{[19
]}

Andratschke, N. ^{[2
]}

机构：

[1] Leopoldina Hosp Schweinfurt, Dept Radiat Oncol, Schweinfurt, Germany

[2] Univ Zurich, Dept Radiat Oncol, Univ Hosp Zurich, Ramistr 100, CH-8091 Zurich, Switzerland

[3] Strahlentherapie Bautzen, Radiat Oncol, Bautzen, Germany

[4] Krankenhaus Barmherzige Bruder, Radiat Oncol, Regensburg, Germany

[5] RadioChirurg CyberKnife Sudwest, Radiat Oncol, Goppingen, Germany

[6] Univ Klinikum Schleswig Holstein, Radiat Oncol, Kiel, Germany

[7] Heidelberg Univ, Univ Hosp Mannheim, Radiat Oncol, Heidelberg, Germany

[8] Univ Hosp Freiburg, Radiat Oncol, Freiburg, Germany

[9] Tech Univ Munich, Klinikum Rechts Isar, Radiat Oncol, Munich, Germany

[10] Univ Munich, LMU Munich, Dept Radiat Oncol, Munich, Germany

[11] Univ Hosp Heidelberg, Radiat Oncol, Heidelberg, Germany

[12] Univ Hosp Rostock, Radiat Oncol, Rostock, Germany

[13] Univ Hosp Wurzburg, Radiat Oncol, Wurzburg, Germany

[14] Univ Hosp Halle, Radiat Oncol, Halle, Germany

[15] Univ Hosp Basel, Radiat Oncol, Basel, Switzerland

[16] Univ Med Ctr Hamburg Eppendorf, Radiat Oncol, Hamburg, Germany

[17] Strahlenzentrum Hamburg, Radiat Oncol, Hamburg, Germany

[18] Univ Hosp Cologne, Radiat Oncol, Cologne, Germany

[19] Klinikum Passau, Radiat Oncol, Passau, Germany

来源：

RADIOTHERAPY AND ONCOLOGY | 2017年 / 123卷 / 02期

关键词：

Frailty models; Liver metastases; Stereotactic radiotherapy; SBRT; Tumor control probability modeling; CELL LUNG-CANCER; RADIATION-THERAPY; CONTROL PROBABILITY; COLORECTAL-CANCER; SURVIVAL; SBRT; OLIGOMETASTASES; MODELS;

D O I：

10.1016/j.radonc.2017.01.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction:, Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology. Methods: 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database. Histology was considered through random effects in semi parametric and parametric frailty models. Dose prescriptions were parametrized by conversion to the maximum biologically effective dose using alpha/beta of 10 Gy (BEDmax). Results: After adjusting for histology, BEDmax was the strongest predictor of TCP. Larger PTV volumes, chemotherapy prior to SBRT and simple motion management techniques predicted significantly lower TCP. The model predicted a BED of 209 +/- 67 Gy(10) necessary for 90% TCP at 2 years with no prior chemotherapy, but 286 +/- 78 Gy(10) when chemotherapy had been given. Breast cancer metastases were significantly more responsive to SBRT compared to other histologies with 90% TCP at 2 years achievable with BED,. of 157 +/- 80 Gy(10) or 80 +/- 62 Gy(10) with and without prior chemotherapy, respectively. Conclusions: Besides dose, histology and pretreatment chemotherapy were important factors influencing local TCP in this large cohort of liver metastases. After adjusting for prior chemotherapy, our data add to the emerging evidence that breast cancer metastases do respond better to hypofractionated SBRT compared to other histologies. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：227 / 233

页数：7

共 34 条

[31] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up [J].

Vansteenkiste, J. ;

Crino, L. ;

Dooms, C. ;

Douillard, J. Y. ;

Faivre-Finn, C. ;

Lim, E. ;

Rocco, G. ;

Senan, S. ;

Van Schil, P. ;

Veronesi, G. ;

Stahel, R. ;

Peters, S. ;

Felip, E. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1462-1474

[32] IMAGE-GUIDED ROBOTIC STEREOTACTIC BODY RADIATION THERAPY FOR LIVER METASTASES: IS THERE A DOSE RESPONSE RELATIONSHIP? [J].

Vautravers-Dewas, Claire ;

Dewas, Sylvain ;

Bonodeau, Francois ;

Adenis, Antoine ;

Lacornerie, Thomas ;

Penel, Nicolas ;

Lartigau, Eric ;

Mirabel, Xavier .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03) :E39-E47

[33]

Wienke A., 2007, THESIS

[34] Stereotactic radiotherapy of primary liver cancer and hepatic metastases [J].

Wulf, Joern ;

Guckenberger, Matthias ;

Haedinger, Ulrich ;

Oppitz, Ulrich ;

Mueller, Gerd ;

Baier, Kurt ;

Flentje, Michael .

ACTA ONCOLOGICA, 2006, 45 (07) :838-847

← 1 2 3 4 →